The BASE facility is focused on the production and research into synthetic DNA and RNA technologies.
The BASE facility is located in the Australian Institute of Bioengineering and Nanotechnology (AIBN) at the University of Queensland, and hosts state-of-the-art equipment and bioprocessing technologies, with a team of skilled and experienced scientists to provide leading edge nucleic-acid production capabilities.
The BASE facility provides synthetic RNA and DNA to support Australian research
. This support includes manufacturing high-quality nucleic acids, including mRNA vaccines and therapies, double-stranded RNA and plasmid DNA vectors.
We offer end-to-end services, from the project and construct design, scalable manufacture, formulation and final product characterisation, with each step supported by rigorous quality control.
The BASE team leverages these unique capabilities to research synthetic RNA and DNA technologies. We focus on developing early-stage innovative technologies with commercial outcomes.
We are developing new RNA technologies, building optimised manufacturing processes (including enzymatic DNA synthesis and enzyme engineering), and applying these advances for innovative clinical, industrial and agricultural uses.
Synthetic nucleic-acids are central to a range of therapies, from templates for the production of recombinant proteins and antibodies, the development of cell lines, to the direct use of nucleic acids in vaccines.
BASE, in partnership with TIA, PEF and NBF, supports the production and use of synthetic nucleic-acids for translational use, including pre-clinical and early clinical leads.
BASE facility works closely with industrial and agricultural partners to develop synthetic nucleic-acids for commercial applications. This includes the use of nucleic-acids in pest control, veterinary vaccines, and crop science.
BASE supports commercial partners, ranging from early-stage start-ups to large multinational companies, in developing prototypes and products according to their specific needs.